Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eliglustat + immune checkpoint inhibitor + regorafenib
- Development stage
- Unknown
- Lead developer
- Chinese PLA General Hospital
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This appears to be a combination of three different therapeutic agents: eliglustat (a glucosylceramide synthase inhibitor), an unspecified immune checkpoint inhibitor, and regorafenib (a multi-kinase inhibitor). Regorafenib is an oral multi-kinase inhibitor that blocks proteins involved in tumor growth and angiogenesis, approved for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma. There is no established clinical use of this specific three-drug combination in current medical practice.
02
Targets
BRAF (B-Raf proto-oncogene, serine/threonine kinase)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDCD1 (Programmed cell death protein 1 receptor)CD274 (Programmed cell death protein 1 ligand 1)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)UGCG (UDP-glucose ceramide glucosyltransferase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on eliglustat + immune checkpoint inhibitor + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eliglustat + immune checkpoint inhibitor + regorafenib.